相似文献
1
Neoadjuvant Chemotherapy prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer: A Systematic Review.
Chemother Res Pract. 2013;2013:386809. doi: 10.1155/2013/386809. Epub 2013 Feb 21.
2
A systematic review of the role of adjuvant and neoadjuvant pharmacotherapy in patients undergoing radical prostatectomy.
Expert Opin Pharmacother. 2012 Jul;13(10):1421-36. doi: 10.1517/14656566.2012.690398. Epub 2012 May 30.
3
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Urology. 2003 Dec 29;62 Suppl 1:55-62. doi: 10.1016/j.urology.2003.09.052.
4
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
J Urol. 2009 Apr;181(4):1672-7; discussion 1677. doi: 10.1016/j.juro.2008.11.121. Epub 2009 Feb 23.
5
Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
BJU Int. 2007 Aug;100(2):274-80. doi: 10.1111/j.1464-410X.2007.06760.x. Epub 2007 Mar 12.
6
7
Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Urology. 1997 Mar;49(3A Suppl):65-9. doi: 10.1016/s0090-4295(97)00171-4.
8
Neoadjuvant hormone therapy and radical prostatectomy: the jury is still out.
Eur Urol. 2001;39 Suppl 1:10-4. doi: 10.1159/000052544.
9
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
J Clin Oncol. 2008 Oct 20;26(30):4928-33. doi: 10.1200/JCO.2007.15.0441. Epub 2008 Sep 15.
10
[Impact of androgen deprivation prior to radical prostatectomy for T1, T2 prostate cancer on the likelihood of curative surgery].
Nihon Hinyokika Gakkai Zasshi. 1997 Nov;88(11):936-44. doi: 10.5980/jpnjurol1989.88.936.
引用本文的文献
1
Head-to-head comparisons of [Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1240-1251. doi: 10.1007/s00259-022-06047-6. Epub 2022 Nov 22.
本文引用的文献
1
A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: effect on apoptosis.
Urology. 2012 Aug;80(2):484.e17-22. doi: 10.1016/j.urology.2012.02.027. Epub 2012 Apr 13.
2
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Cancer. 2012 Oct 1;118(19):4777-84. doi: 10.1002/cncr.27416. Epub 2012 Jan 26.
3
Cancer statistics, 2012.
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
4
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
World J Surg Oncol. 2012 Jan 4;10:1. doi: 10.1186/1477-7819-10-1.
5
A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
J Urol. 2011 Sep;186(3):882-7. doi: 10.1016/j.juro.2011.04.087. Epub 2011 Jul 24.
6
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Eur Urol. 2011 Apr;59(4):572-83. doi: 10.1016/j.eururo.2011.01.025. Epub 2011 Jan 25.
7
EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.
Eur Urol. 2011 Jan;59(1):61-71. doi: 10.1016/j.eururo.2010.10.039. Epub 2010 Oct 28.
8
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Cancer. 2010 Apr 1;116(7):1699-708. doi: 10.1002/cncr.24960.
9
Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: a phase II trial.
Urol Oncol. 2011 Nov-Dec;29(6):608-13. doi: 10.1016/j.urolonc.2009.09.012. Epub 2009 Dec 21.
10
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.
Br J Cancer. 2009 Oct 20;101(8):1248-52. doi: 10.1038/sj.bjc.6605320. Epub 2009 Sep 15.
Zotero 插件